Heart attacks and strokes are among the leading causes of death globally, with millions suffering from cardiovascular diseases (CVD) every year. There are more than seven million people in the UK alone, with about 100,000 patients experiencing heart attacks annually. However, a group of researchers at University College London (UCL) estimate that one 'polypill' taken daily day could eliminate a majority of these cases dramatically lowering death tolls.

The proposed polypill, a combination of a statin and three blood pressure-lowering drugs, has been under study for over two decades. Experts argue that introducing this pill universally for individuals aged 50 and above could be more effective than the current NHS Health Check, which assesses risk factors every five years for those aged between 40 and 74.

Studies have repeatedly proven the effectiveness of the polypill in preventing CVD. A groundbreaking 2019 study in The Lancet found that five years' use of the polypill cut the risk of heart attack and stroke by a third. In addition, previous modelling analyses have estimated that if given universally to people over 55, the polypill might be able to prevent 80% of heart attacks and strokes.

Today, the NHS Health Check follows a risk-based model in which patients are tested for CVD risk factors and treated with drugs accordingly. Yet, as per UCL's study, this system has serious flaws:

Low Uptake: Just 40% of those eligible for the NHS Health Check choose to have it, leaving a considerable number of at-risk patients undiagnosed and untreated.

Ineffective Prediction of Risk: The majority of heart attacks and strokes happen to people at average risk levels, thus making it challenging to identify the need for intervention effectively.

Limited Effectiveness: Even at maximum take-up, the NHS Health Check programme is predicted to have fewer health impacts compared to a polypill initiative applied to the whole population.

Simplicity and Affordability of the Polypill Strategy

One of the big benefits of the polypill is that it is so easy. In contrast to the existing screening-based model, the polypill scheme would not involve complicated medical tests or lengthy risk assessments. Instead, people reaching 50 would just have to fill out a few questions to determine possible side effects before they were prescribed.

Professor Aroon Hingorani of the UCL Institute of Cardiovascular Science, one of the strongest proponents of this scheme, says:

"Finally, the time is now to do much better on prevention. A population approach would prevent a lot more heart attacks and strokes than is done today with a strategy of trying to target a smaller group only."

Aside from the possible health implications, the polypill is also an economic solution. The drugs used are off-patent, thus cheap to produce and distribute. With the vast economic cost of managing CVD-related illnesses, a preventive model could result in substantial cost-saving for the NHS in the future.

The polypill has been proven to be effective by numerous international trials. In 2019, a randomised trial in rural Iran discovered that participants who took the polypill for five years had a 34% reduced risk of having a heart attack or stroke compared to non-participants.

Likewise, modelling research has indicated that even if only 8% of people aged over 50 took up the polypill regimen, it would still be more beneficial to their health than the NHS Health Check programme.

Is This a Case of Over-Medicalisation?

One of the main objections to the polypill strategy is the suggestion that it might result in the unnecessary medicalisation of a significant proportion of the population. But, it is argued, it should be considered as a preventative measure, not as mass medication.

Professor Sir Nicholas Wald of UCL's Institute of Health Informatics explains:

"Instead of being a 'medicalisation' of a significant proportion of the population, a polypill programme is a prevention measure to prevent an individual from becoming a patient."

He compares it with public health measures like water fluoridation or compulsory seatbelts—interventions that have been shown to have a significant impact in reducing public health danger at low individual cost.

With the evidence in favour of the polypill's effectiveness and viability overwhelming, experts are calling on the NHS to act now. It is their belief that substituting the NHS Health Check with a polypill-based prevention program could be the UK government's flagship policy under its pledge to put disease prevention ahead of cure.

As Professor Hingorani points out, "The status quo is not a justifiable option." With CVD still a major cause of death globally, taking a population-wide polypill approach could be a turning point for preventative medicine, potentially saving thousands of lives annually. The question now is whether the NHS will take up this call and establish a policy with the potential to transform the prevention of cardiovascular disease on a national level.

In an alarming incident, more than 330 children in Pakistan have contracted HIV due to reuse of syringes in a hospital in Pakistan’s Punjab, according to a report.

The report, based on an undercover investigation by BBC News, highlighted blatant infection control failures and unsafe medical practices at THQ Hospital Taunsa in Pakistan.

The failures captured on camera, filmed over 32 hours inside THQ Taunsa Hospital in late 2025, showcase persistent unsafe practices, including the reuse of syringes on multi-dose vials, that have infected more than 330 children with HIV since late 2024.

The footage captured multiple violations of basic hygiene protocols, including the staff reusing syringes on multi-dose medicine vials, which increases the risk of contaminating entire batches of medication. In several instances, the same vial was then used to treat different children, the report said.

Other scenes captured included poor sanitation conditions, such as open vials, used needles left on countertops, and improper disposal of medical waste; staff administering injections without sterile gloves, further increasing the risk of cross-contamination.

Pakistan HIV Cases: Previous Outbreak In Southern Sindh

The incident in Taunsa is not the first. In 2019, media reports cited nearly 1,000 children testing positive for HIV due to the reuse of needles in southern Sindh province.

“Pakistan has experienced a series of HIV outbreaks over the past two decades, but we’ve never before seen this many young children infected or so many health facilities involved," Dr Fatima Mir from the Aga Khan University in Pakistan, told The Guardian. She was the lead author of the paper published in the Lancet Infectious Diseases, which also reported the cases.

“Use of syringes and needles is widespread, and Pakistan has one of the highest rates of unsafe injections in the world. Health practitioners need to use intravenous treatment only when necessary, use needles only once, and screen blood for infections before using it for transfusions,” she added.

The India Case: Thalassemic Children Infected With HIV

In 2025, a dozen children undergoing blood transfusions for thalassemia contracted HIV in two different incidents in India's Madhya Pradesh and Jharkhand, highlighting “systemic lapses in blood bank regulations”.

At least six children were found HIV positive at Satna district hospital in Madhya Pradesh, allegedly due to contaminated blood transfusions at the district hospital during treatment for thalassemia.

The children affected include five boys aged under 11 and a nine-year-old girl who have been undergoing blood transfusions at the hospital.

Another six children with thalassemia reportedly contracted HIV from contaminated blood transfusions at a government hospital in the West Singhbhum district of Jharkhand.

Safe Injection Practices: What Is Recommended

The World Health Organization (WHO) mandates the use of single-use, safety-engineered syringes—specifically auto-disable (AD) or reuse-prevention (RUP) devices—to prevent disease transmission and needle-stick injuries.

These devices automatically lock or break after one use and are essential for immunization and medication administration.

The US CDC recommends using single-dose vials whenever possible, over multiple-dose vials, especially when medications will be administered to multiple patients.

Do not administer medications from a syringe to multiple patients, even if the needle or cannula on the syringe is changed.

The US Food and Drug Administration has recalled China-made over-the-counter cough drops and throat lozenges sold across the country over potential safety concerns.

The FDA in a notice stated that Xiamen Kang Zhongyuan Biotechnology from Xiamen in China, has issued a voluntary recall of numerous products based on March 20, 2026.

The regulator noted that the recall was started following the FDA’s recommendation based on observations noted during an August 15, 2025, inspection of the manufacturing facility that “may bear on product quality.”

The FDA classified the recall as Class II on April 10, 2026. Class II recalls apply to products that can cause “temporary or medically reversible” health problems.

While the FDA did not specify how many cough drops were under the recall, the recalled products include:

• Exchange Select (manufactured for Your Military Exchanges): 30-count bag of honey lemon and menthol flavored cough drops
• Caring Mill (distributed by FSA Store, Inc): 90-count bags of cherry cough drops
• Discount Drug Mart Food Market: 30-count bags of honey lemon cough drops
• MGC Health (distributed by Medical Group Care): 25-count and 30-count bags of sugar-free honey lemon cough drops and 80-count bags of honey lemon cough drops
• QC Quality Choice (distributed by CDMA, Inc): 25-count bags of black cherry sugar-free and regular cough drops; 25-count bags of sugar-free and regular honey lemon cough drops; 30-count bags of creamy strawberry throat soothing drops; 30-count bags of menthol cough drops; and 30-count bags of vanilla honey cough drops.

Safe Alternatives For Cough Drops

Coughs are often caused by viral infections, allergies, or environmental irritants such as dust or smoke.

Also read: Eye Drops: US FDA Recalls Over 3 Million Products Over Safety Concerns

Dr. Umashankar Sharma, Medical In-charge (B.N.Y.S), Kailash Institute of Naturopathy, Ayurveda & Yoga, recommends several safe home remedies that can ease both adults' and children’s discomfort naturally.

“Warm liquids like soups, clear broths, or mild herbal teas, such as chamomile, help keep the throat moist and reduce irritation. Honey is a great natural option for children over one year; half to one teaspoon before bedtime can help calm night-time coughing,” he said.

He also suggests using a cool-mist humidifier in the room to add moisture to the air, which can loosen mucus and ease breathing. Saline nasal drops or a short steam session in a warm shower can also help relieve congestion.

Ensuring plenty of rest and hydration with water or warm drinks is essential. Slightly elevating the head with an extra pillow at night can reduce coughing while sleeping.

These remedies are generally safe and effective. However, if the cough persists for more than two weeks, or if the individual experiences high fever, wheezing, or difficulty breathing, it’s important to consult a doctor to rule out more serious conditions.

Home Remedies For Sore Throat

According to the Centers for Disease Control and Prevention, throat pain linked to an upper respiratory infection usually improves within about a week. Over-the-counter pain relievers like ibuprofen or naproxen can help ease discomfort and may be more effective than acetaminophen because they reduce both pain and inflammation.

Alongside medication, certain home remedies may also provide relief. Options worth trying include saltwater gargle, honey and herbal tea, or other hot beverages such as soups.

A new designation has begun circulating in COVID-19 headlines—the “Cicada” variant, scientifically known as BA.3.2.

First reported in November 2024, it has since been identified in more than 20 countries, drawing attention as the virus continues to evolve in early 2026. Although the terminology is recent, the broader context remains familiar: BA.3.2 is part of the Omicron lineage but has a distinctive history.

It traces back to the BA.3 lineage, which largely disappeared from global circulation in 2022, only to reappear after nearly two years of minimal detection. The nickname “Cicada” reflects this pattern—much like the insect that remains hidden for years before emerging suddenly, the variant appears to have evolved quietly before re-entering circulation.

Where Did The Cicada Variant Come From After Disappearing?

Unlike most variants that spread in a steady, stepwise fashion, BA.3.2 appears to have taken a less direct path. It carries more than 70 mutations in its spike protein, prompting closer scrutiny of its potential to spread or evade immunity. Yet there is no clear evidence that BA.3 circulated continuously at low levels.

Instead, scientists point to alternative explanations: prolonged infection in an immunocompromised individual, undetected evolution in regions with limited genomic surveillance, or even circulation in an animal host before re-entering humans. Such pathways can produce variants that seem to “jump” ahead evolutionarily rather than emerge gradually.

Despite its striking mutation profile, BA.3.2 has so far shown only limited and sporadic spread. More than a year after its initial detection, it has not triggered major outbreaks or displaced other Omicron sub-lineages. This pattern indicates that, under current levels of population immunity, the variant lacks a clear transmission advantage.

While its evolutionary trajectory remains scientifically intriguing, its real-world impact has been modest—underscoring a broader point: not every highly mutated variant becomes a significant public health threat.

What Does It Mean For Virus Evolution And Surveillance?

The emergence of variants like “Cicada” offers a timely reminder that SARS-CoV-2 evolution remains unpredictable at times. First, such evolutionary pathways can lead to more mutations, particularly in the spike protein, raising concerns about partial immune escape or changes in transmissibility.

Second, they highlight gaps in global surveillance, underscoring the need for more consistent and widespread sequencing efforts. Third, they show that SARS-CoV-2 can still evolve in unexpected, non-linear ways, even within well-known variants such as Omicron.

COVID Variant Cicada Symptoms

Current observations indicate that infections linked to the “Cicada” variant present symptoms like those of other Omicron strains, including

1. Fever
2. Cough
3. Sore throat
4. Fatigue

Doctors have not found any distinct clinical pattern observed so far. Despite its notable mutation profile, there is no conclusive evidence that BA.3.2 leads to more severe disease. Health authorities continue to track the variant through ongoing genomic surveillance. At present, the absence of increased severity, along with sustained protection from existing immunity against serious outcomes, suggests that BA.3.2 behaves much like other Omicron sub-lineages—something to watch closely, but not a fundamentally new threat.

Does The ‘Cicada’ Variant Threaten Vaccine Protection?

The emergence of the “Cicada” variant (BA.3.2) has prompted a more thorough evaluation of its potential risks, particularly regarding vaccine efficacy. Its high number of spike protein mutations raises concerns about possible immune escape and altered transmissibility, as these changes could reduce the ability of vaccine- or infection-derived antibodies to fully neutralize the virus.

This is especially relevant given the variant’s unusual evolutionary path—re-emerging after a prolonged period of apparent dormancy, during which it may have accumulated mutations outside routine surveillance.

However, current evidence suggests that while some reduction in protection against infection is possible, vaccines are still expected to provide strong protection against severe disease, hospitalization, and death, as seen with other Omicron sub-lineages.

Importantly, BA.3.2 has not shown increased severity or global dominance, and its clinical profile remains similar to earlier Omicron variants.

For now, the “Cicada” variant is a reminder rather than a turning point—a sign that the virus continues to explore new evolutionary paths, even if not all of them lead to global waves.